We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 108.24 | 109.30 | 109.37 | 0 | 01:00:00 |
From May 2019 to May 2024
By Michael Dabaie
Zymeworks Inc. (ZYME) said its global biopharma partner Celgene Corp. (CELG) selected a lead therapeutic candidate in oncology for further development and exercised its option to a commercial license under the companies' collaboration and licensing agreement.
Zymeworks said it will receive a $7.5 million payment as a result of Celgene's exercise of its option to a commercial license.
Under the terms of the original 2014 agreement, Zymeworks granted Celgene a license to research, develop, and commercialize up to eight bispecific antibodies, and in 2018, the companies increased the number of potential products to 10. For each, Zymeworks is eligible to receive up to $164 million comprised of a licensing fee and development and commercial milestones in addition to royalties on worldwide sales.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 16, 2019 09:10 ET (13:10 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
